Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 janv. 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h00 HE
|
Olema Oncology
SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer,...
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
07 déc. 2022 15h37 HE
|
Olema Oncology
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting toxicities, and no observed drug-drug interactionNo induced metabolism of...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 déc. 2022 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)
21 nov. 2022 09h16 HE
|
Olema Oncology
SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Company’s complete...
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
08 nov. 2022 16h30 HE
|
Olema Oncology
Presented preliminary results from OP-1250 Phase 1/2 dose expansion study demonstrating favorable tolerability, high drug exposure, and strong anti-tumor activity at the 34th EORTC-NCI-AACR...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 nov. 2022 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology to Present at Upcoming Investor Conferences in November
01 nov. 2022 08h00 HE
|
Olema Oncology
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
26 oct. 2022 03h00 HE
|
Olema Oncology
OP-1250 continues to demonstrate favorable tolerability, high drug exposure, and strong anti-tumor activity in preliminary Phase 1/2 study results presented at the 34th EORTC-NCI-AACR SymposiumInitial...
Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
12 oct. 2022 07h01 HE
|
Olema Oncology
SAN FRANCISCO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the Company will present updated clinical results from the...